Zoetis Inc. Forecasted to Post Q3 2017 Earnings of $0.63 Per Share (ZTS)
Zoetis Inc. (NYSE:ZTS) – Research analysts at Jefferies Group issued their Q3 2017 EPS estimates for Zoetis in a report issued on Thursday. Jefferies Group analyst J. Holford forecasts that the company will post earnings of $0.63 per share for the quarter. Jefferies Group also issued estimates for Zoetis’ FY2017 earnings at $2.34 EPS, FY2018 earnings at $2.70 EPS, FY2019 earnings at $3.05 EPS, FY2020 earnings at $3.44 EPS and FY2021 earnings at $3.75 EPS.
Zoetis (NYSE:ZTS) last posted its earnings results on Tuesday, August 8th. The company reported $0.53 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.53. Zoetis had a net margin of 17.50% and a return on equity of 62.49%. The firm had revenue of $1.27 billion for the quarter, compared to analysts’ expectations of $1.27 billion. During the same quarter last year, the firm earned $0.49 EPS. The company’s quarterly revenue was up 5.0% compared to the same quarter last year.
A number of other equities research analysts have also recently commented on ZTS. Zacks Investment Research cut shares of Zoetis from a “buy” rating to a “hold” rating in a report on Tuesday, July 4th. Cowen and Company set a $60.00 price target on shares of Zoetis and gave the company a “buy” rating in a report on Tuesday, July 11th. Deutsche Bank AG reiterated a “buy” rating and set a $65.00 price target (up previously from $62.00) on shares of Zoetis in a report on Monday, July 17th. Stifel Nicolaus reiterated a “buy” rating and set a $65.00 price target on shares of Zoetis in a report on Friday, July 21st. Finally, Goldman Sachs Group, Inc. (The) reiterated a “neutral” rating and set a $62.00 price target on shares of Zoetis in a report on Monday, August 7th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and twelve have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $65.76.
Zoetis (NYSE ZTS) opened at 63.74 on Friday. The firm’s 50 day moving average is $64.54 and its 200 day moving average is $61.63. Zoetis has a 52-week low of $46.86 and a 52-week high of $66.35. The company has a market cap of $31.18 billion, a PE ratio of 36.03 and a beta of 1.02.
The firm also recently declared a quarterly dividend, which will be paid on Friday, December 1st. Shareholders of record on Thursday, November 9th will be given a $0.105 dividend. The ex-dividend date of this dividend is Wednesday, November 8th. This represents a $0.42 annualized dividend and a yield of 0.66%. Zoetis’s payout ratio is presently 23.73%.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Sii Investments Inc. WI raised its position in Zoetis by 0.3% in the first quarter. Sii Investments Inc. WI now owns 7,161 shares of the company’s stock worth $383,000 after acquiring an additional 23 shares during the period. Ironwood Investment Management LLC raised its position in Zoetis by 0.7% in the second quarter. Ironwood Investment Management LLC now owns 6,870 shares of the company’s stock worth $429,000 after acquiring an additional 48 shares during the period. Benjamin F. Edwards & Company Inc. raised its position in Zoetis by 1.3% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 4,201 shares of the company’s stock worth $262,000 after acquiring an additional 55 shares during the period. Wilbanks Smith & Thomas Asset Management LLC raised its position in Zoetis by 1.8% in the second quarter. Wilbanks Smith & Thomas Asset Management LLC now owns 5,682 shares of the company’s stock worth $354,000 after acquiring an additional 98 shares during the period. Finally, First Manhattan Co. raised its position in Zoetis by 1.1% in the second quarter. First Manhattan Co. now owns 9,099 shares of the company’s stock worth $567,000 after acquiring an additional 99 shares during the period. Institutional investors and hedge funds own 93.54% of the company’s stock.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.